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Cystic fibrosis (CF) is a common life-threatening autosomal recessive disorder in the Caucasian population, and the gene
responsible is the CF transmembrane conductance regulator (CFTR). Patients with CF have repeated bacterial infection of the
airways caused by Pseudomonas aeruginosa (PA), which is one of the predominant pathogen, and endobronchial chronic
infection represents a major cause of morbidity and mortality. Pentraxin 3 (PTX3) is a gene that encodes the antimicrobial
protein, PTX3, which is believed to have an important role in innate immunity of lung. To address the role of PTX3 in the risk of
PA lung colonization, we investigated five single nucleotide polymorphisms of PTX3 gene in 172 Caucasian CF patients who
were homozygous for the F508del mutation. We observed that PTX3 haplotype frequencies were significantly different
between patients with PA colonization, as compared with noncolonized patients. Moreover, a protective effect was found in
association with a specific haplotype (odds ratio 0.524). Our data suggest that variations within PTX3 affect lung colonization of
Pseudomonas in patients with CF.
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Cystic fibrosis (CF) is a complex condition affecting a
number of organs, including the exocrine pancreas,
intestine, sweat glands and lung; the effects of the latter
are the major cause of disease morbidity and early
mortality. Identification of the CF transmembrane con-
ductance regulator (CFTR) gene in 1989
1 was followed
by discovery of hundreds of mutant CFTR alleles
(CFTR database on www.genet.sickkids.on.ca/) and by
attempts at genotype–phenotype correlations.
2 The asso-
ciations between CFTR genotype and exocrine pancreatic
and sweat gland phenotypes were soon found to be
greater than the association between CFTR genotype and
the pulmonary phenotype.
2,3 The clinical outcome of
pulmonary disease in CF patients is extremely variable,
even among patients with the same CFTR genotype. This
variability could arise from some combination of
environmental and modifier gene effects.
Patients with CF have repeated bacterial infection of
the airways since the first month of life; Pseudomonas
aeruginosa (PA) is one of the predominant pathogen and
can lead to endobronchial chronic infection. Pathogen
recognition is one of the key mechanisms of innate
immunity, and is mediated by transmembrane, cytosolic
and secreted soluble pattern recognition receptors.
4
Pentraxin 3 (PTX3) is a prototypic long pentraxin that
has a nonredundant role in the antimicrobial response
against multiple pathogens including PA.
5
Pentraxins are a superfamily of conserved proteins that
are characterized by a cyclic multimeric structure, usually
pentameric structure.
6–9 The classical short pentraxins,
C-reactive protein and serum amyloid P component, are
acute-phase proteins produced in the liver in response to
inflammatory mediators. PTX3 shares similarities with the
classical short pentraxins; however, it has an unrelated
long amino-terminal domain coupled to the carboxy-
terminal pentraxin domain, and differs in gene organiza-
tion, cellular source and ligands recognition.
9 PTX3 is
rapidly produced and released by several cell types, in
particular by mononuclear phagocytes, dendritic
cells, fibroblasts and endothelial cells,
9–11 in response to
primary inflammatory signals. PTX3 binds the comple-
ment component C1q, the extracellular matrix component
tumor necrosis factor-a-induced protein 6 and selected
microorganisms such as PA with high affinity.
Studies in PTX3-deficient mice suggest that PTX3 has a
role in innate resistance to bacterial infection, such as PA.
Lung infection of PTX3-deficient mice by PA showed an
increase in mortality and lung colonization.
12 Moreover,
a role for PTX3 gene, as potential modifier, has been
hypothesized for susceptibility to pulmonary tuberculo-
sis in an African population.
13
The human PTX3 gene, localized on human chromo-
some 3 band q25, is organized in three exons separated
by two introns and covers B7Kb (Figure 1). We analyzed
five single nucleotide polymorphisms (SNPs) of PTX3,
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www.nature.com/gene(without including any other gene in the analysis), which
included three intronic (rs2305619, rs1840680 and
rs3845978) and two exonic (synonymous mutation in
rs35948036, nonsynonymous mutation in rs3816527)
(Table 1) SNPs. The allelic frequency in Caucasian
population for the SNPs rs2305619, rs3594S036 and
rs3845978 was reported in NCBI database, whereas
SNPs rs1840680 and rs3816527 were validated by our
group in a control population.
In this work, we analyzed the role of five SNPs of
PTX3 in 127 CF Caucasian patients homozygous for
F508del (age X11 years), for the development of chronic
PA colonization.
The genotype-allele distribution for PTX3 polymorph-
isms followed the Hardy–Weinberg equilibrium, and
allelic frequencies were comparable among patients
and controls (Table 2a). Allelic distribution of five PTX3
polymorphisms was analyzed in 75 CF patients with
chronic PA colonization (PA patients), as compared with
52 subjects without evidence of persistent PA growth
in bronchial secretions (non-PA patients) (Table 2b).
Analysis of SNPs frequencies in CF patients has shown
that distribution of two intronic SNPs (rs1840680 and
rs2305619) and one exonic SNP (rs3816527) were
different between group of patients with or without PA
chronic colonization. In particular, statistical analysis has
shown that the intronic rs2305619 and rs1840680 alleles
5’ 6,97 kb
PTX3
rs3816527
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rs2305619
rs35948036
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Exon
Intron
Figure 1 PTX3 gene maps with position of SNPs.
Table 1 Single nucleotide polymorphism (SNP) information
SNP ID Alleles Peptide
shift
Synonymous
change
Peptide
location (aa)
rs2305619 A/G
rs3816527 C/A Ala - Asp No 48
rs1840680 A/G
rs3845978 C/T
rs35948036 C/T None (Leu) Yes 16
Abbreviations: Ala, alanine; Asp, aspartic acid; Leu, leucine. We
examined 127 (70 females, 57 males, age range, 11–52 years)
Caucasian patients homozygous for the F508del mutation, who
were followed up at the Regional Cystic Fibrosis centre of Verona
(Italy). The study protocol was approved by Verona Azienda
Ospedaliera and Brescia Spedali Civili Ethics Committees. Patients
and parents of minors provided written informed consent. Clinical,
biological and functional data were obtained retrospectively from
patients’ hospital records. To validate allelic frequencies of SNPs in
our population, we have collected cord blood samples from a total
of 165 children (72 females, 93 males) from the Department of
Obstetrics at Spedali Civili of Brescia.
Table 2a Frequency distributions of PTX3 gene single nucleotide
polymorphisms (SNPs) in patients and controls
SNPs Associated
allele
Frequencies in
CF patients
(n¼127)
Frequencies
in controls
(n¼165)
w
2 P-value
rs2305619 A 0.508 0.461 1.285 0.257
rs1840680 A 0.504 0.448 1.771 0.183
rs3845978 T 0.028 0.027 0.000 0.983
rs35948036 C 0.016 0.000 5.233 0.022
rs3816527 C 0.453 0.397 1.832 0.176
Abbreviations: CF, cystic fibrosis; CFTR, CF transmembrane
conductance regulator; PTX3, pentraxin 3.
All DNA samples were extracted using a standard salting out
procedure. DNA samples were estimated by a spectrophotometer
and final concentrations were determined. Samples were genotyped
by TaqMan SNP assay (5ng of DNA in 25ml reaction volume;
Applied Biosystems, Carlsbad, CA, USA) using ABI PRISM 7000
Sequence Detection System. Fluorescence curves were analyzed
with the 7000 Sequence Detection Software v.1.1 for allelic discrimina-
tion. All samples were analyzed for five SNPs in PTX3, including
three intronic (rs2305619, rs1840680 and rs3845978) and two exonic
(synonymous mutation in rs35948036, D48A nonsynonymous mutation
in rs3816527) SNPs. The diagnosis of CF was established on the basis
of the results of two sweat chloride tests (460mmoll
 1), performed
according to Gibson and Cooke
22 and the identification of mutations in
the CFTR gene.
Table 2b Frequency distributions of PTX3 gene single nucleotide
polymorphisms (SNPs) in patients with (PA) and without (non-PA)
PA colonization
SNPs Associated
allele
Frequencies in
PA patients
(n¼75)
Frequencies
in non-PA
patients
(n¼52)
w
2 P-value
rs2305619 A 0.573 0.413 6.281 0.012
rs1840680 A 0.567 0.413 5.767 0.016
rs3845978 C 0.980 0.962 0.781 0.377
rs35948036 C 0.020 0.010 0.467 0.513
rs3816527 C 0.507 0.375 4.297 0.038
Abbreviations: CF, cystic fibrosis; PTX3, pentraxin 3. The Pseudo-
monas aeruginosa (PA) colonization was defined as the presence of
PA in at least three consecutive sputum cultures collected in a
6-month period. To have an adequate clinical history, we have
selected CF patients who were X11 years old. Age at the time of
first PA colonization is reported for each patient with bacterial
colonization (75 patients: 39 females, 36 males; age range, 11–45
years), whereas chronological age at the time of the study is
reported for patients without PA colonization (52 patients: 31
females, 21 males; age range, 11–52 years). The two groups of
patients were comparable for age (CF with PA colonization
20.5±0.78 years versus CF without PA colonization 23.3±1.37
years) and for sociodemographic variables. The two groups of
patients were followed up in the same time periods, thus under-
going similar protocols of eradications of PA. As a definition of
chronic colonization, we adopted the most widely accepted, that is,
presence of Pseudomonas in sputum, in three samples obtained in a
period of 1 year. Chronic colonization was not reversible in our
patients. On the other hand, patients not colonized by PA were
consistently found Pseudomonas-free and did not undergo specific
anti-Pseudomonas treatments in the attempt to eradicate the germ. To
correct for multiple testing, we performed 1000 permutations
(HaploView 4.2).
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Genes and Immunityand the exonic allele rs3816527 are statistically associated
(w
2-test: P¼0.012, P¼0.016 and P¼0.038, respectively)
with PA colonization. However, after permutation test
(1000 permutations), PA colonization was significantly
associated only with rs2305619.
Analysis of distribution of SNP genotypes among
patients (Table 3) has revealed a recessive model for
exonic SNPs (rs35948036 and rs3816527) and a dominant
model for intronic SNPs (rs2305619 and rs1840680).
Although we could not define the phenotype model for
the intronic SNP, rs3845978, because the genotype T/T
was not observed in our patients group, calculation of
odds ratio (OR) values on the basis of a dominant model
for SNPs rs2305619 (OR¼2.69; 95% confidence interval
(CI): 1.14–6.35) and rs1840680 (OR¼2.54; 95% CI: 1.07–
6.00) have shown a positive association with PA
colonization, suggesting that these SNPs might increase
the risk of bacterial colonization in CF patients. In
contrast, calculation of OR on the basis of a recessive
model for exonic SNPs rs35948036 (OR¼0.72, 95%
CI¼0.06–8.11) and rs3816527 (OR¼0.54, 95% CI¼0.25–
1.14) suggests that these genotypes might be protective
for PA colonization.
Next, we have compared the haplotype frequencies
between PA patients and non-PA patients (Table 4). We
observed that the two haplotypes, T-A-G-A-G and T-A-
C-A-C (SNPs position: rs35948036-rs2305619-rs3816527-
rs1840680-rs3845678) are significantly associated (T-G-A-
G-C, P¼0.016; T-A-C-A-C, P¼0.037). In particular, we
observed that T-G-A-G-C haplotype was present in
54.6% of CF patients not colonized by PA, as compared
with 39.3% of PA-colonized patients. In contrast, the
haplotype T-A-C-A-C was present at higher frequency in
PA patients (50.0%), as compared with noncolonized
patients (36.8%). After permutation test, no haplotype
association preserved a significant P-value; therefore,
haplotype analysis was restricted to a sub-group of
SNPs. Firstly, we have analyzed the haplotype that
included the three SNPs associated with PA colonization
(intronic SNPs rs2305619 and rs1840680, exonic SNP
rs3816527). Analysis of the G-A-G haplotype has shown
that this haplotype (P-value¼0.012, w
2¼6.281) was
present in 58.7% of non-PA patients (42.7% of PA
patients), whereas the A-C-A haplotype (P-value¼0.038,
w
2¼4.297) was more common in PA patients (50.7%),
as compared with non-PA colonized patients (37.5%).
After permutation test, G-A-G haplotype preserved a
significant P-value (0.030). Secondly, we have added the
other exonic SNP rs35948036 to the analysis of these
three SNPs (rs2305619, rs1840680 and rs3816527). Even
after this analysis, we observed a similar trend. The T-G-
A-G haplotype (P-value¼0.007) was more common in
Table 3 Genotype distribution of SNPs in PA and non-PA patients
Model Frequency (%) OR (95% CI) P-value
PA Not PA
rs35948036 Codominant T/T 73 (97.4) 51 (98.1) Reference category 0.570
C/T 1 (1.3) 1 (1.9) 1.43 (0.09–23.42)
C/C 1 (1.3) 0 (0) 0.00 (0.00–NA)
Dominant T/T 73 (97.3) 51 (98.1) Reference category 0.780
C/T–C/C 2 (2.7) 1 (1.9) 0.72 (0.06–8.11)
Recessive T/T–C/T 74 (98.7) 52 (100) Reference category 0.300
C/C 1 (1.3) 0 (0) 0.00 (0.00–NA)
rs2305619 Codominant A/A 27 (36) 9 (17.3) Reference category 0.045
A/G 32 (42.7) 25 (48.1) 2.34 (0.94–5.87)
G/G 16 (21.3) 18 (34.6) 3.37 (1.23–9.28)
Dominant A/A 27 (36) 9 (17.3) Reference category 0.019
A/G–G/G 48 (64) 43 (82.7) 2.69 (1.14–6.35)
Recessive A/A–A/G 59 (78.7) 34 (65.4) Reference category 0.098
G/G 16 (21.3) 18 (34.6) 1.95 (0.88–4.32)
rs3816527 Codominant A/A 20 (26.7) 21 (40.4) Reference category 0.130
A/C 34 (45.3) 23 (44.2) 0.64 (0.26–1.45)
C/C 21 (28) 8 (15.4) 0.36 (0.13–1.01)
Dominant A/A 20 (26.7) 21 (40.4) Reference category 0.110
A/C–C/C 55 (73.3) 31 (59.6) 0.54 (0.25–1.14)
Recessive A/A–A/C 54 (72) 44 (84.6) Reference category 0.090
C/C 21 (28) 8 (15.4) 0.47 (0.19–1.16)
rs1840680 Codominant A/A 26 (34.7) 9 (17.3) Reference category 0.059
A/G 33 (44) 25 (48.1) 2.19 (0.87–5.49)
G/G 16 (21.3) 18 (34.6) 3.25 (1.18–8.69)
Dominant A/A 26 (34.7) 9 (17.3) Reference category 0.028
A/G–G/G 49 (65.3) 43 (82.7) 2.54 (1.07–6.00)
Recessive A/A–A/G 59 (78.7) 34 (65.4) Reference category 0.098
G/G 16 (21.3) 18 (34.6) 1.95 (0.88–4.32)
rs3845978 — C/C 72 (96) 48 (92.3) Reference category 0.370
C/T 3 (4) 4 (7.7) 2.00 (0.43–9.34)
Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio; PA, Pseudomonas aeruginosa; SNP, single nucleotide polymorphism.
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Genes and Immunitynoncolonized patients (57.7%) than in PA-colonized
patients (40.7%), whereas, the T-A-C-A haplotype (P-
value¼0.038) was present in 50.7% of PA patients, as
compared with 37.5% of non-PA patients. After permu-
tation test, the T-G-A-G haplotype preserved a signifi-
cant P-value (0.029). Haplotype trend regression analyses
were followed by linkage disequilibrium analysis within
PTX3 gene, using the HaploView software (Broad Institute,
C a m b r i d g e ,M A ,U S A ;F i g u r e2 ) .
We have observed a significant association of one
PTX3 polymorphism with chronic PA lung colonization
in CF patients with homozygous F508del CFTR muta-
tion. A haplotype association in PTX3 gene was also
identified in these patients, suggesting that PTX3 protein
is involved in preventing lung colonization by this
opportunistic pathogen in CF patients. A previous study
by Olesen et al.
13 reported an association of the same
PTX3 haplotype with pulmonary tuberculosis risk in
West Africa, in particular, a lower frequency of the
rs2305619, rs3816527 and rs1840680 SNPs was observed
in patients with pulmonary tuberculosis, as compared
with control population. The results of our study, which
will need further confirmations, suggest that the same
haplotype (rs2305619, rs3816527 and rs1840680) was
protective for risk of lung colonization by PA in CF
patients. These observations sustain the hypothesis that
the long pentraxin PTX3 has a nonredundant function in
microbial recognition and subsequent clearance of
microbial pathogens of the lower respiratory tract,
including PA and Mycobacterium tuberculosis. PTX3 is
stored in specific granules of neutrophils and in other
intracellular storage compartments of dendritic cells and
monocytes, ready to be released in response to inflam-
matory and/or microbial stimuli.
14 Once PTX3 is
Table 4 PTX3 haplotype trend regression results for extended haplotypes
rs35948036 rs2305619 rs3816527 rs1840680 rs3845978 Frequency w
2 P-value OR (95% CI)
CF patients PA Not PA
T G A G C 0.456 0.393 0.546 5.762 0.016 0.54 (0.26–1.10)
T A C A C 0.446 0.500 0.368 4.368 0.037 1.72 (0.83–3.54)
T A A A C 0.051 0.060 0.038 0.587 0.444
T G A G T 0.021 0.013 0.031 0.955 0.329
C G A G C 0.016 0.020 0.010 0.427 0.513
rs2305619 rs3816527 rs1840680 Frequency w
2 P-value OR (95% CI)
CF patients PA Not PA
G A G 0.492 0.427 0.587 6.281 0.012 0.52 (0.26–1.07)
A C A 0.453 0.507 0.375 4.297 0.038 1.71 (0.83–3.53)
A A A 0.051 0.060 0.038 0.587 0.444
rs35948036 rs2305619 rs3816527 rs1840680 Frequency w
2 P-value OR (95% CI)
CF patients PA Not PA
T G A G 0.476 0.407 0.577 7.137 0.007 0.50 (0.25–1.03)
T A C A 0.453 0.507 0.375 4.297 0.038 1.71 (0.83–3.53)
T A A A 0.051 0.060 0.038 0.587 0.444
C G A G 0.016 0.020 0.010 0.427 0.513
Abbreviations: CF, cystic fibrosis; CI, confidence interval; OR, odds ratio; PA, Pseudomonas aeruginosa; PTX3, pentraxin 3; SNP, single
nucleotide polymorphism.
Statistical analysis has shown significant association of the haplotypes, as indicated above. To correct for multiple testing, we performed 1000
permutations using HaploView 4.2; statistical significance was preserved for the G-A-G and the T-G-A-G haplotypes.
Patients with PA Patients without PA
Figure 2 HaploView figures. Linkage disequilibrium (LD) plots
characterizing haplotype blocks in PTX3 gene. In the first column are
LD plots for PA colonization patients and in the second column are LD
plots for patients without PA colonization. D0 values are indicated in
percentages within squares in the LD plot, with solid blocks without
numbers indicating D0 ¼1 (100%) for the corresponding pair of
variants. Strong LD is indicated by dark gray, whereas light gray and
white indicate uninformative and low confidence values, respectively.
LD Blocks were created with the default algorithm in HaploView that
creates 95% confidence bounds on D0 considered to be in strong LD,
where 95% of the comparisons made are informative. The haplotype
blocks were created using HaploView program, version 4.2.
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Genes and Immunityreleased in the extracellular space, it can bind specific
pathogens such as fungi, bacteria and viruses, promoting
their phagocytosis and removal from tissues.
15,16
Although the clinical heterogeneity of lung disease in
CF patients with the same CFTR mutation is related to
multiple genetic and environmental factors, it is cur-
rently well established that chronic lung colonization by
PA represents an important determinant for the progres-
sion of lung damage in CF patients. Because we have
observed that a specific haplotype of PTX3 gene is
associated with chronic PA colonization of the lung in CF
patients, it is likely that the genetic variants of PTX3
might ultimately influence the severity of CF lung
disease. However, we failed to detect in our cohort of
CF patients any correlation of respiratory parameters,
including FEV1, with any PTX3 gene polymorphisms,
suggesting that the contribution of these genetic variants
to lung disease progression needs to be investigated in a
larger sample of CF patients. This observation is in
agreement with a previous report by Tesse et al.
17,
showing that specific gene polymorphisms of the DEFB1
gene encoding for the antimicrobial peptide b-defensin-1
are associated with chronic PA colonization, but do not
correlate with abnormal lung function parameters. Other
investigators have sought to associate genetic variations
in genes encoding for cytokines with a key role in
inflammatory response with lung disease progression in
CF.
18 However, no genetic variants of the genes encoding
for cytokines such as tumor necrosis factor-a, lympho-
toxin-a, interleukin (IL) 1-b, IL-1 receptor antagonist,
IL-6, IL-8 and IL-10 were linked with impairment of lung
function.
18 Although variants in the gene encoding for
the transforming growth factor-b 1 were associated with
lung function decline in a large cohort of CF patients, it
was not confirmed in a smaller cohort.
19
Analysis of genetic variants in the mannose-binding
lectin (MBL) gene in children and adults with CF has
revealed that adult patients who were homozygous for
the rare variant of MBL had significantly reduced
survival, as compared with patients carrying the com-
mon genotypes.
20 However, this association of MBL
variants with lung functions was not reproducible in the
pediatric cohort, unless after correction for confounding
factors.
21 Similarly, the use of proportional hazards
regression models has shown that in patients carrying
specific IL-8 variants, PA chronic colonization occurs at
an older age of 18 years, suggesting a protective effect of
this gene against lung disease progression.
It is interesting that all the studies seeking to establish
a correlation between lung disease progression and/or
PA chronic colonization with genetic variants of modifier
genes have revealed a key role for genes encoding
antimicrobial proteins such as DEFB, MBL and PTX3,o r
for IL-8, which encodes for the neutrophil chemotactic
protein IL-8. Because all these antimicrobial proteins and
the chemotactic factor IL-8 are released in large amounts
during lung infections, it is conceivable to hypothesize
that their genetic variants might confer susceptibility/
resistance against common opportunistic pathogens that
are isolated from CF patients with respiratory infection.
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